Form 6-K Clearmind Medicine Inc. For: Sep 17

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: September 2026

 

Commission file number: 001-41557

 

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

 

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on September 17, 2026, titled “Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.”.

 

 

EXHIBIT INDEX

 

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Clearmind Medicine, Inc.
	(Registrant)
Date: September 17, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE TITLED: "CLEARMIND MEDICINE DELIVERS BRIEFING TO FDA FOLLOWING INVITATION TO HISTORIC PSYCHEDELIC HEARING IN WASHINGTON, D.C."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Clearmind Medicine testifies at FDA psychedelic hearing in D.C.
• IQST - IQSTEL Reaches $450 Million Annualized Revenue Run Rate Based on $37.5 Million in July Net Revenue
• Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach